{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:40:58Z","timestamp":1793727658574,"version":"4.6.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,3,29]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Baseline metabolic tumor volume is a strong prognostic factor in early-stage HL. Baseline metabolic tumor volume affects the early response to treatment and, combined with early PET, improves risk stratification.<\/jats:p>","DOI":"10.1182\/blood-2017-07-795476","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T13:10:56Z","timestamp":1517490656000},"page":"1456-1463","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":181,"title":["Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial"],"prefix":"10.1182","volume":"131","author":[{"given":"Anne-S\u00e9gol\u00e8ne","family":"Cottereau","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Cochin Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Paris Descartes University, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annibale","family":"Versari","sequence":"additional","affiliation":[{"name":"Santa Maria Nuova Hospital\u2013IRCCS Reggio Emilia, Reggio Emilia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Loft","sequence":"additional","affiliation":[{"name":"Department of Clinical Physiology, Nuclear Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"Hematology Department, INSERM 1231, University Hospital, Dijon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bellei","sequence":"additional","affiliation":[{"name":"Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Ricci","sequence":"additional","affiliation":[{"name":"Lymphoma Academic Research Organization (LYSARC) Lymphoma Study Association Imaging, H\u00f4pital Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bardet","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Centre de Lutte Contre le Cancer Fran\u00e7ois Baclesse, Caen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Castagnoli","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Ospedale Santo Stefano, Prato, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Brice","sequence":"additional","affiliation":[{"name":"Hematology, Hopital Saint-Louis, AP-HP, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Raemaekers","sequence":"additional","affiliation":[{"name":"Hematology, Radboud University Medical Center, Nijmegen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Deau","sequence":"additional","affiliation":[{"name":"Hematology, H\u00f4pital Cochin, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Fortpied","sequence":"additional","affiliation":[{"name":"European Organisation for Research and Treatment of Cancer, Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiana","family":"Raveloarivahy","sequence":"additional","affiliation":[{"name":"European Organisation for Research and Treatment of Cancer, Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie","family":"Van Zele","sequence":"additional","affiliation":[{"name":"Lymphoma Academic Research Organization (LYSARC) Lymphoma Study Association Imaging, H\u00f4pital Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Chartier","sequence":"additional","affiliation":[{"name":"Biostatistical Department, LYSARC, Centre Hospitalier Lyon Sud, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Vander Borght","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, Centre Hospitalo-Universitaire Universit\u00e9 Catholique de Louvain, Namur, Yvoir, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[{"name":"Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Andre","sequence":"additional","affiliation":[{"name":"Hematology Department, Centre Hospitalo-Universitaire Universit\u00e9 Catholique de Louvain, Namur, Yvoir, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Meignan","sequence":"additional","affiliation":[{"name":"Lymphoma Study Association Imaging, H\u00f4pital Henri Mondor, Cr\u00e9teil, France; and"},{"name":"Universit\u00e9 Paris Est, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"Suppl 3","key":"2019111903185106900_B1","doi-asserted-by":"crossref","first-page":"iii70","DOI":"10.1093\/annonc\/mdu181","article-title":"Hodgkin\u2019s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Eichenauer","year":"2014","journal-title":"Ann Oncol"},{"issue":"19","key":"2019111903185106900_B2","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin\u2019s disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2019111903185106900_B3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/annonc\/11.suppl_1.S81","article-title":"Treatment of Hodgkin\u2019s disease: results and current concepts of the German Hodgkin\u2019s Lymphoma Study Group","volume":"11","author":"Sieber","year":"2000","journal-title":"Ann Oncol"},{"issue":"5","key":"2019111903185106900_B4","doi-asserted-by":"crossref","first-page":"554","DOI":"10.6004\/jnccn.2015.0075","article-title":"Hodgkin lymphoma, version 2.2015","volume":"13","author":"Hoppe","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"25","key":"2019111903185106900_B5","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111903185106900_B6","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/1097-0142(19880415)61:8<1719::AID-CNCR2820610834>3.0.CO;2-A","article-title":"Tumor burden as the most important prognostic factor in early stage Hodgkin\u2019s disease. Relations to other prognostic factors and implications for choice of treatment","volume":"61","author":"Specht","year":"1988","journal-title":"Cancer"},{"issue":"1","key":"2019111903185106900_B7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.critrevonc.2013.11.002","article-title":"Tumor burden in Hodgkin\u2019s lymphoma: much more than the best prognostic factor","volume":"90","author":"Gobbi","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"2019111903185106900_B8","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","article-title":"Impact of risk factors on outcomes in early-stage Hodgkin\u2019s lymphoma: an analysis of international staging definitions","volume":"24","author":"Klimm","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"2019111903185106900_B9","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood-2014-12-616474","article-title":"Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma","volume":"126","author":"Ceriani","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2019111903185106900_B10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","article-title":"Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL","volume":"43","author":"Mikhaeel","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2019111903185106900_B11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/annonc\/mdw011","article-title":"Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL)","volume":"27","author":"Cottereau","year":"2016","journal-title":"Ann Oncol"},{"issue":"15","key":"2019111903185106900_B12","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma","volume":"22","author":"Cottereau","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"30","key":"2019111903185106900_B13","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111903185106900_B14","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/cas.12282","article-title":"Metabolic tumor volume by positron emission tomography\/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin\u2019s lymphoma","volume":"104","author":"Song","year":"2013","journal-title":"Cancer Sci"},{"issue":"9","key":"2019111903185106900_B15","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","article-title":"Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma","volume":"41","author":"Kanoun","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"2019111903185106900_B16","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111903185106900_B17","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage i and ii Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111903185106900_B18","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO.2009.22.4089","article-title":"Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials","volume":"27","author":"Meignan","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111903185106900_B19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111903185106900_B20","doi-asserted-by":"crossref","first-page":"e0140830","DOI":"10.1371\/journal.pone.0140830","article-title":"Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to predict survival in Hodgkin lymphoma","volume":"10","author":"Kanoun","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"2019111903185106900_B21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","article-title":"FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","volume":"37","author":"Boellaard","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"2019111903185106900_B22","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","article-title":"Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients","volume":"41","author":"Meignan","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"2019111903185106900_B23","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on Interim-PET-Scan in Lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"27","key":"2019111903185106900_B24","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111903185106900_B25","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"15 suppl","key":"2019111903185106900_B26","article-title":"Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial [abstract]","volume":"34","author":"Casasnovas","year":"2016","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111903185106900_B27","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","article-title":"Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2019111903185106900_B28","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood-2015-07-653386","article-title":"Quantitative FDG-PET: a new biomarker in PMBCL","volume":"126","author":"Meignan","year":"2015","journal-title":"Blood"},{"issue":"19","key":"2019111903185106900_B29","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1182\/blood-2016-10-744292","article-title":"Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report","volume":"129","author":"Tout","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2019111903185106900_B30","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3324\/haematol.2016.141846","article-title":"Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes","volume":"101","author":"Kumar","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"2019111903185106900_B31","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1200\/JCO.2001.19.5.1388","article-title":"Image-aided estimate of tumor burden in Hodgkin\u2019s disease: evidence of its primary prognostic importance","volume":"19","author":"Gobbi","year":"2001","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111903185106900_B32","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111903185106900_B33","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1016\/S2352-3026(16)30108-9","article-title":"The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin\u2019s lymphoma: a retrospective, European, multicentre cohort study","volume":"3","author":"Agostinelli","year":"2016","journal-title":"Lancet Haematol"},{"issue":"Suppl S2","key":"2019111903185106900_B34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hon.2437_53","article-title":"Response-adjusted therapy for advanced Hodgkin lymphoma (RATHL trial): longer follow up confirms efficacy of de-escalation after a negatve interim PET scan (CRUK\/07\/033)","volume":"35","author":"Trotman","year":"2017","journal-title":"Hematol Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/13\/1456\/1404428\/blood795476.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/13\/1456\/1404428\/blood795476.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:19:06Z","timestamp":1574133546000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/13\/1456\/36613\/Prognostic-value-of-baseline-metabolic-tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,29]]},"references-count":34,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018,3,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-07-795476","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,29]]}}}